Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1

被引:40
|
作者
Gullbo, J [1 ]
Wickström, M
Tullberg, M
Ehrsson, H
Lewensohn, R
Nygren, P
Luthman, K
Larsson, R
机构
[1] Uppsala Univ, Div Clin Pharmacol, Dept Med Sci, SE-75185 Uppsala, Sweden
[2] Univ Gothenburg, Dept Chem, SE-41296 Gothenburg, Sweden
[3] Karolinska Inst, Karolinska Pharm, SE-17176 Stockholm, Sweden
[4] Karolinska Inst, Dept Oncol Pathol, SE-17176 Stockholm, Sweden
[5] Univ Uppsala Hosp, Dept Oncol Radiol & Clin Immunol, SE-75185 Uppsala, Sweden
关键词
peptichemio; P2; J1; melphalan; alkylating peptides; hydrolysis;
D O I
10.1080/10611860310001647140
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recently, we presented a series of melphalan containing di- and tripeptides with high cytotoxic activity and J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) was identified as one of the most interesting compounds. It was speculated that the increased activity compared to melphalan itself, demonstrated both in vitro and in vivo, resided in increased transport over the tumour cell membrane and/or hydrolytic cleavage and liberation of melphalan inside the cells. Indeed, overexpression of hydrolytic enzymes like peptidases, esterases and proteases has been described in several types of human malignancies, thus providing a target for selective chemotherapy. In this work, the details of the increased activity was further investigated and potential tumour selectivity is discussed. The intracellular delivery of melphalan is investigated in detail using peptidase resistant dipeptide derivatives, by enzyme inhibitors and probes for enzymatic activity and by studying the time dependency of drug effect as well as intracellular drug concentrations (cellular pharmacokinetics). The results show that the activity of the dipeptide mustards is highly dependent on intracellular hydrolysis, which result in rapid intracellular release of the alkylating unit (i.e. free melphalan) in cells with high enzymatic activity. The maximum intracellular melphalan concentration following J1 exposure was reached already after 15 min, thereafter declining with a half-life of approximately 1 h. This rapid intracellular loading resulted in less reduction of activity for J1 than for melphalan and six other standard drugs when human tumour cell lines were exposed to the drugs for a limited time ( simulating short half-life in vivo). Peptidase inhibitors inhibited the activity and intracellular release of melphalan, and dipeptide derivatives designed to resist the action of peptidases was less active than the corresponding normal dipeptide.
引用
收藏
页码:355 / 363
页数:9
相关论文
共 50 条
  • [1] Anti-Myeloma Activity of Enzymatically Activated Melphalan Prodrug J1
    Chauhan, Dharminder
    Bandi, Madhavi
    Singh, Ajita V.
    Podar, Klaus
    Richardson, Paul G.
    Munshi, Nikhil C.
    Viktorsson, Kristina
    Lewensohn, Rolf
    Spira, Jack
    Anderson, Kenneth C.
    BLOOD, 2010, 116 (21) : 767 - 767
  • [2] Anti-tumour activity of bisphosphonates in human myeloma cells
    Shipman, CM
    Rogers, MJ
    Apperley, JF
    Russell, RGG
    Croucher, PI
    LEUKEMIA & LYMPHOMA, 1998, 32 (1-2) : 129 - 138
  • [3] MECHANISMS OF ACTION OF ANTI-TUMOUR POLYSACCHARIDES .1. EFFECTS OF ANTILYMPHOCYTE SERUM ON ANTI-TUMOUR ACTIVITY OF LENTINAN
    MAEDA, YY
    HAMURO, J
    CHIHARA, G
    INTERNATIONAL JOURNAL OF CANCER, 1971, 8 (01) : 41 - +
  • [5] ISOLATION OF A SUBPOPULATION OF ADHERENT PERITONEAL CELLS WITH ANTI-TUMOUR ACTIVITY
    NATHAN, CF
    HILL, VM
    TERRY, WD
    NATURE, 1976, 260 (5547) : 146 - 148
  • [6] NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity
    Albertsson, PA
    Basse, PH
    Hokland, M
    Goldfarb, RH
    Nagelkerke, JF
    Nannmark, U
    Kuppen, PJK
    TRENDS IN IMMUNOLOGY, 2003, 24 (11) : 603 - 609
  • [7] Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
    N Ioannou
    A G Dalgleish
    A M Seddon
    D Mackintosh
    U Guertler
    F Solca
    H Modjtahedi
    British Journal of Cancer, 2011, 105 : 1554 - 1562
  • [8] Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
    Ioannou, N.
    Dalgleish, A. G.
    Seddon, A. M.
    Mackintosh, D.
    Guertler, U.
    Solca, F.
    Modjtahedi, H.
    BRITISH JOURNAL OF CANCER, 2011, 105 (10) : 1554 - 1562
  • [9] Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate
    Qiu, L
    Kelso, MJ
    Hansen, C
    West, ML
    Fairlie, DP
    Parsons, PG
    BRITISH JOURNAL OF CANCER, 1999, 80 (08) : 1252 - 1258
  • [10] Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate
    L Qiu
    M J Kelso
    C Hansen
    M L West
    D P Fairlie
    P G Parsons
    British Journal of Cancer, 1999, 80 : 1252 - 1258